Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic, Inc. (Nasdaq: HOLX) generates a steady flow of news centered on women’s health, medical technology innovation and corporate developments. As a company that describes itself as focused on developing technologies to detect, diagnose and treat health conditions, many of its announcements highlight advances in diagnostics, breast imaging, oncology testing and digital pathology.
Investors and healthcare professionals following HOLX news will find updates on Hologic’s diagnostic platforms, such as the Panther and Panther Fusion systems, including regulatory milestones like FDA clearance and CE marking for new assays. Recent communications have covered automated molecular tests for gastrointestinal bacterial pathogens, which expand the company’s infectious disease testing menu and illustrate its emphasis on rapid, molecular-based diagnostics.
Hologic’s news feed also features developments in breast health technologies. The company has publicized data on its AI-powered mammography tools, such as the Genius AI Detection solution and 3DQuorum imaging technology, through studies conducted at major medical centers and presented in peer-reviewed journals or at scientific meetings. These stories often focus on how artificial intelligence can support radiologists by flagging suspicious areas on mammograms and streamlining image review without compromising cancer detection performance.
Oncology and precision medicine are recurring themes. Hologic and its subsidiary Biotheranostics, Inc. issue updates about the Breast Cancer Index Test, including new clinical evidence presented at conferences like the San Antonio Breast Cancer Symposium. These releases describe how the test may inform extended endocrine therapy decisions for patients with early-stage, hormone receptor–positive breast cancer and examine its performance in various patient subgroups.
Beyond technology and clinical data, Hologic’s news includes educational initiatives and partnerships, such as the "Ultimate Defense" cervical cancer screening awareness campaign with professional basketball player Erica Wheeler, and collaborations in epigenomics and pharmaco-epigenetics through Hologic Diagenode and co-marketing agreements. Corporate and financial announcements, including quarterly earnings releases and the proposed acquisition of Hologic by funds managed by Blackstone and TPG, provide additional context for HOLX stockholders.
For readers interested in HOLX news, this page offers a centralized view of Hologic’s product milestones, clinical research, public health campaigns and transaction-related updates, making it a useful resource for tracking how the company’s activities evolve over time.
Hologic, Inc. (Nasdaq: HOLX) has launched its innovative Genius™ Digital Diagnostics System in Europe, enhancing cervical cancer screening with artificial intelligence and advanced imaging. This system aims to identify pre-cancerous lesions and cervical cancer cells more effectively. The Genius system is designed to improve lab efficiency and workflow while promoting collaboration among laboratories. Customer feedback has been overwhelmingly positive, highlighting its potential to transform screening processes and enhance patient outcomes.
Hologic, Inc. (NASDAQ: HOLX) is set to launch the NovaSure® V5 global endometrial ablation device at the AAGL 50th Global Congress (November 14-17). This innovative device, building on a 20-year legacy of the NovaSure system, aims to enhance the physician experience. With over 3 million treatments performed since its FDA approval in 2001, the device incorporates advanced features like the EndoForm™ cervical seal technology and SureClear™ fluid removal system. The launch reflects Hologic's commitment to improving outcomes for women and providing physicians with reliable tools.
Hologic, Inc. (HOLX) reported a fiscal Q4 2021 revenue of $1.317 billion, slightly below last year but exceeding expectations. GAAP diluted EPS was $1.28, down 31.9% year-over-year, while non-GAAP diluted EPS was $1.61, down 22.2%. The company anticipates solid growth in core women's health businesses for fiscal 2022, projecting revenues of $3.750B to $4.000B. Key highlights include a 47% annual revenue growth driven by women's health and COVID-19 testing, although COVID-19 assay sales decreased substantially. Strong operational cash flow of $465.4 million was reported for Q4.
Hologic, Inc. has launched the Aptima® SARS-CoV-2/Flu Assay for simultaneous detection of SARS-CoV-2, influenza A, and influenza B. The assay, CE-Marked for Europe and FDA authorized, provides results in approximately three hours and can process over 1,000 tests daily. This multiplex test addresses the overlap of symptoms between these viruses, enhancing testing options as the flu season approaches. Hologic has distributed over 100 million SARS-CoV-2 assays globally.
Hologic, Inc. has partnered with Mediflix to release Carolina, a documentary-style film highlighting the breast cancer journey. Launched during Breast Cancer Awareness Month, this film guides patients from diagnosis to reconstruction. Featuring testimonials from survivors and experts, Carolina aims to enhance understanding of minimally invasive surgical options, such as the Reconstructive Lumpectomy. This innovative approach uses Hologic’s BioZorb marker to improve cosmetic outcomes post-surgery, addressing the emotional concerns of patients.
Black Women’s Health Imperative and Hologic hosted a roundtable, Unmuting Fibroids: Getting Loud for Equal Care, addressing disparities in uterine fibroid care. Experts emphasized that understanding menstruation as a vital health sign is crucial for prioritizing care. Uterine fibroids affect 80% of Black women, leading to severe health implications. Key initiatives include improving education for healthcare providers, advocating for funding legislation, and promoting culturally competent care to reduce disparities. Hologic supports this through its Project Health Equality.
Hologic, Inc. (NASDAQ: HOLX) has announced the acquisition of Bolder Surgical for approximately $160 million. This strategic move aims to diversify Hologic's surgical portfolio by adding advanced vessel sealing devices. Bolder's products are expected to enhance surgical efficiency, particularly in OB/GYN applications, capitalizing on a larger market potential. The acquisition is forecasted to generate $10 million in revenue this year and is expected to be slightly dilutive to earnings in fiscal 2022, with a break-even outlook for fiscal 2023.
Hologic, Inc. (NASDAQ: HOLX) will release its fourth quarter fiscal 2021 financial results on Monday, November 1, after market close. A conference call hosted by management will take place at 4:30 p.m. ET. Interested participants can join by calling 800-458-4121 (US/Canada) or +1 323-794-2093 (international) with access code 2820462. A replay will be available post-call through December 1, 2021. Additionally, the call will be accessible via a live webcast on the company’s website at www.investors.hologic.com.
Hologic, Inc. has launched the Novodiag® system across Europe, enhancing its molecular diagnostic solutions portfolio. This fully automated diagnostic tool tests for infectious diseases and antimicrobial resistance, following the acquisition of Mobidiag in June 2021. The Novodiag system utilizes real-time PCR and microarray technologies, allowing for rapid multiple pathogen identification from a single sample. It features a CE-IVD test menu for gastrointestinal infections and SARS-CoV-2 detection, with a strong pipeline of future assays.
Hologic, Inc. (NASDAQ: HOLX) has initiated a series of educational initiatives aimed at reducing racial disparities in breast cancer screening. To kick off Breast Cancer Awareness Month, CEO Steve MacMillan will ring the Nasdaq opening bell on October 4. The company is focusing on raising awareness of annual mammograms and addressing inequalities in care, particularly for Black women, who are less likely to receive necessary screenings. Hologic is also collaborating with RAD-AID to improve access to screening services in underserved areas.